Selection criteria for antifungals: the right patients and the right reasons

International Journal of Antimicrobial Agents

Volumn 27, Issue SUPPL. 1, 2006, Pages 17-20

  Chandrasekar, Pranatharthi ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal therapy; Aspergillosis; Candidiasis; Combination treatment; Invasive fungal infections; Zygomycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FUNGEMIA; HUMAN; MORTALITY; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; DRUG THERAPY, COMBINATION; HUMANS; MYCOSES; RISK FACTORS; TREATMENT OUTCOME; ZYGOMYCOSIS;

EID: 33646911055     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.03.014     Document Type: Article

References (15)

1. Groll A.H., Shah P.M., Mentzel C., Schneider M., Just-Nuebling G., and Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33 (1996) 23-32
2. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., and Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 (2004) 309-317
3. Rex J.R., Walsh T.J., Sobel J.D., et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 30 (2000) 662-678
4. Rex J.H., Pappas P.G., Karchmer A.W., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidaemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36 (2003) 1221-1228
5. Kullberg B.J., Sobel J.D., Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet 366 (2005) 1435-1442
6. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
7. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
8. Ostrosky-Zeichner L., Marr K.A., Rex J.H., and Cohen S.H. Amphotericin B: time for a new "gold standard". Clin Infect Dis 37 (2003) 415-425
9. Petraitis V., Petraitiene R., Sarafandi A.A., et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 187 (2003) 1834-1843
10. Marty F.M., Cosimi L.A., and Baden L.R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350 (2004) 950-952
11. Siwek G.T., Dodgson K.J., de Magalhaes-Silverman M., et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 39 (2004) 584-587
12. Imhof A., Balajee S.A., Fredricks D.N., Englund J.A., and Marr K.A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 39 (2004) 743-746
13. Greenberg R.N., Amstead G., Hebrecht R., et al. Posaconazole experience in the treatment of zygomycosis. Proceedings of the 43rd interscience conference on antimicrobial agents and chemotherapy. Chicago, September 14-17 (2003) Abstr M-1756
14. Larkin J.A., and Monero J.A. Efficacy and safety of amphotericin B lipid complex for Zygomycosis. Infect Med 20 (2003) 201-206
15. Perfect J.R. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 40 Suppl. 6 (2005) S401-S408